Assistant Professor
University of Kansas
LAWRENCE, KS, United States
Meredith Hartley graduated from Dartmouth College earning her AB degree in biophysical chemistry with high honors. She continued her education at Massachusetts Institute of Technology where she earned a PhD in biological chemistry working with Dr. Barbara Imperiali. Her thesis work focused on the biosynthesis of complex sugars that decorate proteins on the extracellular surfaces of bacteria.
Following graduate school, Dr. Hartley moved to Oregon Health & Science University (OHSU) in Portland, Oregon and made the pivot in her research focus to hormones and neurodegenerative diseases. As a postdoctoral fellow with Dr. Thomas Scanlan, she validated the use of thyromimetics for treating diseases of myelin damage including multiple sclerosis and an inborn error of metabolism called X-linked adrenoleukodystrophy. This work resulted in several publications, patents, presentations, and press releases. The therapeutic strategy supported by Dr. Hartley’s work is currently under clinical development by Autobahn Therapeutics. Dr. Hartley was awarded a National Multiple Sclerosis Society Postdoctoral Fellowship that supported her research at OHSU.
Dr. Hartley joined the University of Kansas as an Assistant Professor in January 2020. Her laboratory investigates the connections between brain lipids, hormones, and myelin with the goal of developing novel therapies for neurological diseases. Her research is supported by grants from the National Institutes of Health, the American Thyroid Association, and the National Multiple Sclerosis Society.
Disclosure information not submitted.
SY25-02 - Thyroid Hormone Regulation of Microglia during Myelin Damage and Repair
Sunday, June 14, 2026
11:00 AM - 11:30 AM CT